Head-to-head · free
Johnson & Johnson vs Kyntra Bio, Inc.
JNJ vs KYNB — return on capital, cash generation, margins and balance sheet side by side.
JNJ
7 / 8
measures where JNJ leads
KYNB
1 / 8
measures where KYNB leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | JNJ · FY2025 | KYNB · FY2025 |
|---|---|---|
| Revenue | $94.2B | $6.4M |
| Net income | $26.8B | $183.5M |
| Revenue growth (yearly, multi-year) | 3.3% | -59.3% |
| Free cash flow | $19.7B | (4.8M) |
| Free cash flow margin | 20.9% | -74.7% |
| Net cash / (debt) | — | — |
| ROIC | 21.1% | — |
| Return on equity | 35.0% | — |
| Gross margin | 67.9% | 91.4% |
| Operating margin | 27.2% | -704.1% |
| Net debt / EBITDA | 0.73x | 1.06x |
Figures are as reported by each company; latest fiscal year shown.
Where Johnson & Johnson's cash went (FY2025)
- Capital spending
- $4.8B
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Kyntra Bio, Inc.'s cash went (FY2025)
- Capital spending
- $38000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free